{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:27:09Z","timestamp":1784600829459,"version":"3.55.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lupus nephritis (LN) is one of the most severe organ manifestations of systemic lupus erythematosus (SLE). Given its complex pathogenesis and heterogeneous clinical presentation, the clinical management of LN remains challenging. To identify risk factors for LN and provide new insights for its diagnosis and clinical treatment, it is essential to analyze the associations between demographic characteristics, biochemical parameters, clinical features, and immune cell profiles in SLE and LN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study enrolled 121 SLE patients, including 55 with lupus nephritis (LN-positive) and 66 without LN (LN-negative), along with 121 age- and sex-matched healthy controls. Clinical manifestations and laboratory parameters were extracted from medical records for comparative analysis. Differences between groups were assessed using the Mann-Whitney\n                      <jats:italic>U<\/jats:italic>\n                      test and chi-square test. Spearman correlation analysis and regression modeling were employed to evaluate variable associations and their relationship with LN occurrence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Compared to the LN-negative cases, LN patients were younger, had higher SLEDAI-2000 scores, ESR, WBC count, 24-hour urine total protein (24h-UTP), anti-dsDNA and ANA titers (AC-1 homogeneous pattern), and Cystatin-C (CysC), but lower C3 complement levels. They exhibited cutaneous manifestations and edema more frequently and arthritis less frequently. Flow cytometry showed higher circulating lymphocytes, CD3\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells, and PD-1\n                      <jats:sup>+<\/jats:sup>\n                      T cell subsets (CD3\n                      <jats:sup>+<\/jats:sup>\n                      , CD4\n                      <jats:sup>+<\/jats:sup>\n                      , CD8\n                      <jats:sup>+<\/jats:sup>\n                      ) in LN individuals. In LN patients, ESR correlated positively with PD-1\n                      <jats:sup>+<\/jats:sup>\n                      T cell levels. In contrast, in LN-negative cases, anti-dsDNA levels correlated negatively with both age and PD-1\n                      <jats:sup>+<\/jats:sup>\n                      T cell levels. Similarly, SLEDAI-2000 scores correlated negatively with lymphocytes and PD-1\n                      <jats:sup>+<\/jats:sup>\n                      CD3\n                      <jats:sup>+<\/jats:sup>\n                      T cells. Multivariate regression analysis identified 24h-UTP, PD-1\n                      <jats:sup>+<\/jats:sup>\n                      CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells, SLEDAI-2000 score, and edema as independent risk factors for LN in SLE.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Significant differences were observed in both clinical manifestations and serological profiles between LN and LN-negative SLE patients. Notably, elevated PD-1\n                      <jats:sup>+<\/jats:sup>\n                      CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells were identified as an independent risk factor for LN development. These findings suggest that abnormal expansion of PD-1\n                      <jats:sup>+<\/jats:sup>\n                      T lymphocytes may serve as both a diagnostic marker for LN onset and a potential therapeutic target for LN management.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1680747","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:23:33Z","timestamp":1762496613000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A multi-dimensional risk signature for lupus nephritis in systemic lupus erythematosus: integrating symptoms, biochemistry and immune cell profiles"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiaoli","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhefeng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youhua","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/jalm\/jfac036","article-title":"A review of lupus nephritis","volume":"7","author":"Alforaih","year":"2022","journal-title":"J Appl Lab Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.12.008","article-title":"The geoepidemiology of systemic lupus erythematosus","volume":"9","author":"Borchers","year":"2010","journal-title":"Autoimmun Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/bor.0000000000000480","article-title":"Epidemiology of systemic lupus erythematosus: an update","volume":"30","author":"Stojan","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"B5","first-page":"32","article-title":"Correlation of clinical and pathological findings in patients with lupus nephritis: A five-year experience in Iran","volume":"19","author":"Nezhad","year":"2008","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/857316","article-title":"Clinicopathological correlation in asian patients with biopsy-proven lupus nephritis","volume":"2015","author":"Satirapoj","year":"2015","journal-title":"Int J Nephrol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1159\/000081551","article-title":"Renal outcome and predictors of clinical renal involvement in patients with silent lupus nephritis","volume":"98","author":"Wada","year":"2004","journal-title":"Nephron Clin Pract"},{"key":"B8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1191\/0961203305lu2055oa","article-title":"Clinical presentation and monitoring of lupus nephritis","volume":"14","author":"Balow","year":"2005","journal-title":"Lupus"},{"key":"B9","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"102374","DOI":"10.1016\/j.jaut.2019.102374","article-title":"Inflammatory markers in systemic lupus erythematosus","volume":"110","author":"Aringer","year":"2020","journal-title":"J Autoimmun"},{"key":"B11","doi-asserted-by":"publisher","first-page":"102870","DOI":"10.1016\/j.jaut.2022.102870","article-title":"Abnormalities of T cells in systemic lupus erythematosus: new insights in pathogenesis and therapeutic strategies","volume":"132","author":"Li","year":"2022","journal-title":"J Autoimmun"},{"key":"B12","doi-asserted-by":"publisher","first-page":"102283","DOI":"10.1016\/j.coi.2023.102283","article-title":"Immune checkpoint receptors in autoimmunity","volume":"80","author":"Burke","year":"2023","journal-title":"Curr Opin Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0802769","article-title":"Intestinal tolerance is converted to autoimmune enteritis upon pd-1 ligand blockade","volume":"182","author":"Reynoso","year":"2009","journal-title":"J Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.4.2513","article-title":"Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in mrl mice","volume":"181","author":"Lucas","year":"2008","journal-title":"J Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20022119","article-title":"Critical role of the programmed death-1 (Pd-1) pathway in regulation of experimental autoimmune encephalomyelitis","volume":"198","author":"Salama","year":"2003","journal-title":"J Exp Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1145573","article-title":"T peripheral helper cells in autoimmune diseases: what do we know","volume":"14","author":"Huang","year":"2023","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nature20810","article-title":"Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis","volume":"542","author":"Rao","year":"2017","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/art.33488","article-title":"Immunologic characteristics of intrarenal T cells: trafficking of expanded cd8+ T cell B-chain clonotypes in progressive lupus nephritis","volume":"64","author":"Winchester","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.7150\/thno.107418","article-title":"Pd-1 activation mitigates lupus nephritis by suppressing hyperactive and heterogeneous pd-1(+)Cd8(+) T cells","volume":"15","author":"Deng","year":"2025","journal-title":"Theranostics"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12196424","article-title":"Renal biopsy for diagnosis in kidney disease: indication, technique, and safety","volume":"12","author":"Schnuelle","year":"2023","journal-title":"J Clin Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.11.023","article-title":"Revision of the international society of nephrology\/renal pathology society classification for lupus nephritis: clarification of definitions, and modified national institutes of health activity and chronicity indices","volume":"93","author":"Bajema","year":"2018","journal-title":"2004\/2\/1"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/jalm\/jfab140","article-title":"The international consensus on ana patterns (Icap) in 2021-the 6th workshop and current perspectives","volume":"7","author":"Chan","year":"2022","journal-title":"J Appl Lab Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.04.032","article-title":"Epidemiology and management of refractory lupus nephritis","volume":"10","author":"Pons-Estel","year":"2011","journal-title":"Autoimmun Rev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2147\/ijwh.s28034","article-title":"Understanding lupus nephritis: diagnosis, management, and treatment options","volume":"4","author":"Mok","year":"2012","journal-title":"Int J women\u2019s Health"},{"key":"B25","doi-asserted-by":"publisher","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2004.12.045","article-title":"Initial presentation of childhood-onset systemic lupus erythematosus: A french multicenter study","volume":"146","author":"Bader-Meunier","year":"2005","journal-title":"J Pediatr"},{"key":"B27","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1177\/0961203307088006","article-title":"Childhood systemic lupus erythematosus in latin america","volume":"17","author":"Ramirez","year":"2008","journal-title":"Gladel Exp 230 Children. Lupus"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094813","article-title":"Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus","volume":"68","author":"Hoffman","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214436","article-title":"Clinical relevance of hep-2 indirect immunofluorescent patterns: the international consensus on ana patterns (Icap) perspective","volume":"78","author":"Damoiseaux","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.850759","article-title":"Anti-nuclear antibodies patterns in patients with systemic lupus erythematosus and their correlation with other diagnostic immunological parameters","volume":"13","author":"Al-Mughales","year":"2022","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e003608","DOI":"10.1136\/bmjopen-2013-003608","article-title":"Associations between antinuclear antibody staining patterns and clinical features of systemic lupus erythematosus: analysis of a regional swedish register","volume":"3","author":"Frodlund","year":"2013","journal-title":"BMJ Open"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes261","article-title":"Relationship between autoantibody clustering and clinical subsets in sle: cluster and association analyses in hong kong chinese","volume":"52","author":"Li","year":"2013","journal-title":"Rheumatol (Oxford England)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0356-x","article-title":"T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy","volume":"16","author":"Sharabi","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-005122","article-title":"Association of peripheral cd8(+) T cell activation with disease activity and treatment resistance in systemic lupus erythematosus","volume":"11","author":"Fujita","year":"2025","journal-title":"RMD Open"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1718217115","article-title":"Role of pd-1 during effector cd8 T cell differentiation","volume":"115","author":"Ahn","year":"2018","journal-title":"Journal of Immunology."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA120.014745","article-title":"Quantitative phosphoproteomic analysis reveals involvement of pd-1 in multiple T cell functions","volume":"295","author":"Tocheva","year":"2020","journal-title":"J Biol Chem."},{"key":"B37","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12885-017-3062-6","article-title":"Nomogram prediction of individual prognosis of patients with hepatocellular carcinoma","volume":"17","author":"Wan","year":"2017","journal-title":"BMC Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901652","article-title":"Anti-programmed cell death 1 antibody reduces cd4+Pd-1+ T cells and relieves the lupus-like nephritis of nzb\/W F1 mice","volume":"184","author":"Kasagi","year":"2010","journal-title":"Journal of Immunology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/art.39026","article-title":"Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the euro-lupus nephritis cohort","volume":"67","author":"Dall\u2019Era","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.344","article-title":"A prospective study of protein excretion using short-interval timed urine collections in patients with lupus nephritis","volume":"76","author":"Fine","year":"2009","journal-title":"Kidney Int."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1590\/S0101-28002012000100010","article-title":"Urinary protein\/creatinine ratio versus 24-hour proteinuria in the evaluation of lupus nephritis","volume":"34","author":"Solorzano","year":"2012","journal-title":"Jornal brasileiro nefrologia"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000631","article-title":"Clinical measurement of lupus nephritis activity is inferior to biomarker-based activity assessment using the renal activity index for lupus nephritis in childhood-onset systemic lupus erythematosus","volume":"9","author":"Aljaberi","year":"2022"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1680747\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:23:35Z","timestamp":1762496615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1680747\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2025.1680747"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1680747","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"article-number":"1680747"}}